MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Key Highlights
- ➤MiNK will report Q3 2026 financial results before market open November 11
- ➤MiNK will update randomized Phase 2 agenT-797 evaluation in acute lung injury
- ➤ARPA-H-funded collaboration advances room-temperature technologies for deployable cell therapeutics
- ➤New SITC 2026 data support extending iNKT approaches into treatment-resistant cancers
Expert Statements
Jennifer S. Buell, President and Chief Executive Officer of MiNK Therapeutics
“We are entering an important period for MiNK as we advance randomized clinical evaluation of agenT-797 in critical pulmonary illness, expand the reach of our iNKT platform in oncology, and collaborate on technologies designed to overcome longstanding barriers to cell therapy access”
Jennifer S. Buell, President and Chief Executive Officer of MiNK Therapeutics
“Our focus is on translating the unique biology of iNKT cells into meaningful clinical outcomes while building the foundation for therapies that can reach patients wherever they are needed.”
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the third quarter ended September 30, 2026, before the market opens on Wednesday, November 11, 2026.
The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide an update on the randomized clinical development of agenT-797, MiNK's lead iNKT cell therapy, and strategic initiatives supporting the development of scalable, accessible iNKT cell therapies.
Get started
Create a free account to read the full story.